Piramal Pharma Limited (IN:PPLPHARMA)
:PPLPHARMA
Want to see IN:PPLPHARMA full AI Analyst Report?
PPLPHARMA Stock Chart & Stats
₹192.65
-₹4.80(-1.92%)
At close: 4:00 PM EST
₹192.65
-₹4.80(-1.92%)
Day’s Range― - ―
52-Week Range₹132.50 - ₹220.90
Previous CloseN/A
Volume1.66M
Average Volume (3M)264.14K
Market Cap
₹221.85B
Enterprise Value₹273.41B
Total Cash (Recent Filing)₹7.44B
Total Debt (Recent Filing)₹48.51B
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 05, 2026EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)-0.18
Shares Outstanding1,329,248,200
10 Day Avg. Volume501,791
30 Day Avg. Volume264,138
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.22
Price to Sales (P/S)2.04
P/FCF Ratio35.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.44
Revenue Forecast (FY)₹100.93B
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelPiramal Pharma's tri-segment model (CDMO, complex hospital generics, consumer OTC) creates structural revenue diversification. CDMO contracts can yield multi-year, milestone-linked revenues while proprietary generics and OTC products balance volume and brand cashflows, reducing reliance on any single market or product over time.
Sustained Revenue ScalingMeaningful multi-year top-line expansion indicates successful commercial execution and portfolio growth. Sustained revenue scaling supports capacity utilization, bargaining leverage with suppliers and customers, and provides the operating base needed to absorb investments in R&D and manufacturing capacity over the medium term.
Improved Cash GenerationConversion to positive and expanding free cash flow after prior negative years reflects better working-capital management and operational cash discipline. Persistent positive FCF improves funding flexibility for capex, debt servicing, and reinvestment, underpinning medium-term financial resilience if sustained.
Bears Say
Recurring Net LossesThe return to net losses despite revenue growth signals profit-margin and bottom-line pressure beyond core operations, such as elevated non-operating costs or one-offs. Persistent or recurrent losses reduce reinvestment capacity, can erode investor confidence, and make long-term capital allocation harder if not corrected.
Rising Debt LevelsMaterial increases in debt relative to equity raise leverage and interest-service obligations, constraining strategic optionality. If profitability or cash flow weakens again, higher leverage amplifies solvency and liquidity risks and could force prioritization of debt servicing over growth investments over the medium term.
Historical Cash-flow InstabilityWhile FCF turned positive recently, a history of negative free cash flow highlights execution and working-capital variability. Such instability makes sustained reinvestment or predictable deleveraging harder; recurrence of cash-pressure episodes would impair long-term financial flexibility and strategic initiatives.
Piramal Pharma Limited News
PPLPHARMA FAQ
What was Piramal Pharma Limited’s price range in the past 12 months?
Piramal Pharma Limited lowest stock price was ₹132.50 and its highest was ₹220.90 in the past 12 months.
What is Piramal Pharma Limited’s market cap?
Piramal Pharma Limited’s market cap is ₹221.85B.
When is Piramal Pharma Limited’s upcoming earnings report date?
Piramal Pharma Limited’s upcoming earnings report date is Aug 05, 2026 which is in 62 days.
How were Piramal Pharma Limited’s earnings last quarter?
Piramal Pharma Limited released its earnings results on Apr 28, 2026. The company reported ₹0.9 earnings per share for the quarter, missing the consensus estimate of ₹0.96 by -₹0.06.
Is Piramal Pharma Limited overvalued?
According to Wall Street analysts Piramal Pharma Limited’s price is currently Overvalued.
Does Piramal Pharma Limited pay dividends?
Piramal Pharma Limited pays a Notavailable dividend of ₹0.14 which represents an annual dividend yield of 0.08%. See more information on Piramal Pharma Limited dividends here
What is Piramal Pharma Limited’s EPS estimate?
Piramal Pharma Limited’s EPS estimate is -0.86.
How many shares outstanding does Piramal Pharma Limited have?
Piramal Pharma Limited has 1,329,248,200 shares outstanding.
What happened to Piramal Pharma Limited’s price movement after its last earnings report?
Piramal Pharma Limited reported an EPS of ₹0.9 in its last earnings report, missing expectations of ₹0.96. Following the earnings report the stock price went down -2.637%.
Which hedge fund is a major shareholder of Piramal Pharma Limited?
Currently, no hedge funds are holding shares in IN:PPLPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates as a subsidiary of Piramal Enterprises Limited.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Dishman Carbogen Amcis Ltd.
―
Jubilant Ingrevia Ltd.
―
Syngene International Ltd.
―